PhaseRx (NASDAQ:PZRX) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09).
TRADEMARK VIOLATION WARNING: “Laidlaw Downgrades PhaseRx, Inc. (PZRX) to Neutral” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/10/13/laidlaw-downgrades-phaserx-inc-pzrx-to-neutral.html.
An institutional investor recently raised its position in PhaseRx stock. Vanguard Group Inc. lifted its stake in shares of PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 142,182 shares of the company’s stock after acquiring an additional 5,500 shares during the quarter. Vanguard Group Inc. owned about 1.22% of PhaseRx worth $135,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.38% of the company’s stock.
PhaseRx Company Profile
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
What are top analysts saying about PhaseRx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PhaseRx Inc. and related companies.